• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于流行病学的模型估算肿瘤标志物申请不适当的比率。

An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests.

出版信息

Clin Chem Lab Med. 2014 Jun;52(6):889-97. doi: 10.1515/cclm-2013-0708.

DOI:10.1515/cclm-2013-0708
PMID:24501159
Abstract

BACKGROUND

Appropriateness of tumor markers (TMs) has been retrospectively studied in limited patients' series, matching the requests to clinical records. Methods to monitor appropriateness suitable for use on a large scale are required. This study aims to establish and validate an innovative model to estimate appropriateness based on the comparison between the number of TMs requested and the expected requests inferred from epidemiological data.

METHODS

The number of CA15.3, CA19.9 and CA125 requests theoretically expected according to the epidemiology of malignancies in a known geographic area (2 Italian regions) was compared with the number of TMs actually requested - the surveyed requests projected on a regional scale - during a given time span (1 year). The expected number of requests was calculated comparing TMs recommended by guidelines in different clinical scenarios with the prevalence or incidence figures of the examined diseases (carcinomas of breast, pancreas and biliary tract, ovary and endometrium).

RESULTS

Suitability of the model was demonstrated with the analysis of 1,891,070 TM requests surveyed in 66 laboratories from Veneto and Tuscany regions. The percentage difference over the total of expected TMs (delta%) ranged from -6.9% for CA15.3 to +1022.6% for CA19.9 in Veneto and from +35.7% for CA15.3 to +1842.6% for CA19.9 in Tuscany.

CONCLUSIONS

The presented model was effective in demonstrating higher than expected TM request rates, possibly associated with inappropriate use. Moreover, it can be applied on a large scale survey setting since it circumvents the unavailability of clinical information on test orders.

摘要

背景

肿瘤标志物(TMs)的适宜性已在有限的患者系列中进行了回顾性研究,与临床记录的要求相匹配。需要寻找适合大规模使用的监测适宜性的方法。本研究旨在建立和验证一种创新模型,该模型基于通过比较请求的 TM 数量与从流行病学数据推断出的预期请求数量来估计适宜性。

方法

根据已知地理区域(意大利的两个地区)恶性肿瘤的流行病学数据,比较了 CA15.3、CA19.9 和 CA125 请求的理论预期数量与在给定时间段(1 年)内实际请求的 TM 数量——调查请求在区域范围内的投影。通过比较不同临床情况下指南推荐的 TM 与所研究疾病(乳腺癌、胰腺和胆道癌、卵巢和子宫内膜癌)的患病率或发病率数据,计算出预期请求数量。

结果

该模型通过对来自威尼托和托斯卡纳地区的 66 个实验室的 1891070 个 TM 请求进行分析得到了验证。在威尼托,实际请求与预期请求的总差异百分比(delta%)范围从 CA15.3 的-6.9%到 CA19.9 的+1022.6%,而在托斯卡纳,CA15.3 的差异百分比为+35.7%到 CA19.9 的+1842.6%。

结论

所提出的模型在证明高于预期的 TM 请求率方面非常有效,这可能与不适当的使用有关。此外,由于它规避了测试订单临床信息不可用的问题,因此可以应用于大规模调查环境中。

相似文献

1
An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests.基于流行病学的模型估算肿瘤标志物申请不适当的比率。
Clin Chem Lab Med. 2014 Jun;52(6):889-97. doi: 10.1515/cclm-2013-0708.
2
Indicators of inappropriate tumour marker use through the mining of electronic health records.通过挖掘电子健康记录来发现肿瘤标志物使用不当的指标。
J Eval Clin Pract. 2017 Aug;23(4):895-902. doi: 10.1111/jep.12754. Epub 2017 May 15.
3
An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study.基于流行病学的模型作为监测肿瘤标志物申请不当暴发的工具:一项全国范围内的研究。
Clin Chem Lab Med. 2016 Mar;54(3):473-82. doi: 10.1515/cclm-2015-0329.
4
Epidemiology-based assessment of tumor marker overordering in breast cancer: an algorithm to examine different disease conditions.基于流行病学的乳腺癌肿瘤标志物过度检测评估:一种检查不同疾病状况的算法
Int J Biol Markers. 2017 Oct 31;32(4):e471-e473. doi: 10.5301/ijbm.5000274.
5
Overordering of tumor marker for outpatients revealed by performance indicators and the impact of a health policy intervention: An observational study using administrative records.通过绩效指标揭示的门诊患者肿瘤标志物过度订购情况及健康政策干预的影响:一项使用行政记录的观察性研究
Int J Biol Markers. 2023 Mar;38(1):61-71. doi: 10.1177/03936155231154663. Epub 2023 Feb 28.
6
Tumour marker requesting in primary care and the role of the laboratory.基层医疗中的肿瘤标志物请求与实验室的作用。
J Clin Pathol. 2011 May;64(5):443-6. doi: 10.1136/jcp.2010.085357. Epub 2011 Jan 26.
7
Appropriateness of tumor marker request: a case of study.肿瘤标志物检测申请的合理性:一项病例研究
Ann Transl Med. 2017 Jul;5(13):274. doi: 10.21037/atm.2017.06.19.
8
Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial.肿瘤标志物检测:勿失控:一项前瞻性临床试验
Am J Clin Pathol. 2015 Oct;144(4):649-58. doi: 10.1309/AJCPNZAPJRB3T6KK.
9
Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study.沙特阿拉伯西部一所大学附属医院肿瘤标志物申请中的不当实践:一项 3 年回顾性研究。
Int J Biol Markers. 2020 Dec;35(4):35-43. doi: 10.1177/1724600820971305. Epub 2020 Nov 6.
10
Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis.肿瘤标志物检测在临床实践中的应用是否恰当?一项医疗保健理赔数据分析。
Diagnostics (Basel). 2023 Nov 3;13(21):3379. doi: 10.3390/diagnostics13213379.

引用本文的文献

1
Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis.肿瘤标志物检测在临床实践中的应用是否恰当?一项医疗保健理赔数据分析。
Diagnostics (Basel). 2023 Nov 3;13(21):3379. doi: 10.3390/diagnostics13213379.
2
Appropriateness of tumor marker request: a case of study.肿瘤标志物检测申请的合理性:一项病例研究
Ann Transl Med. 2017 Jul;5(13):274. doi: 10.21037/atm.2017.06.19.